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treated with multiple interventions including medications,
invasive procedures, blood product transfusion and utilization
of devices. In some circumstances, the zeal for the use of tech-
nologies and medications may not be balanced by a thorough
appreciation of beneﬁts and risks. One intervention that has
become prevalent in the intensive care unit (ICU) is adminis-
tration of proton pump inhibitors (PPIs). There are two as-
pects of this therapy that are concerning: overuse of PPIs for
acid stress ulcer prophylaxis and the potential contribution
to C. difﬁcile infection.
The frequency of clinically signiﬁcant bleeding in ICU
patients due to stress ulcers has been reported as approxi-
mately 1.5–4%. The risk of signiﬁcant bleeding in critically
ill patients is probably less today due to interventions such
as early use of enteral nutrition and improved resuscitation
to prevent and treat hypoperfusion. Studies from the 1990s
showed that major risk factors for signiﬁcant gastrointestinal
bleeding in ICU patients are mechanical ventilation greater
than 48 h, acute hepatic failure and coagulopathy (interna-
tional normalized ratio >1.5 or partial thromboplastin time
>2 times control value). [1,2] Additional risk factors that
have been suggested include acute and chronic renal failure,
sepsis, hypotension, alcohol abuse, absence of enteral
nutrition, severe head injury, extensive burns and high dose
corticosteroids (>250 mg hydrocortisone or equivalent/day).
Most studies of risk factors suffer from small sample size
and methodological weaknesses.
Currently, stress ulcer prophylaxis may be prescribed inap-
propriately to ICU patients. An Australian study found an
increase in stress ulcer prophylaxis for ICU patients from
67% in 1997 to 86% in 2005. [3] In the same time period,
the use of PPI for stress ulcer prophylaxis increased from
13% to 45%. Stress ulcer prophylaxis has been used unneces-
sarily in ICU patients without signiﬁcant risk of bleeding [4]
and some physicians even prescribe therapy in all ICU patients
regardless of risk [5].PPI use has been associated with a variety of adverse
effects. Perhaps the strongest relationship exists between PPI
use and development of C. difﬁcile infection. Several studies
have also suggested an increased incidence of community-
acquired [6] and nosocomial pneumonia [7]. Long-term use
of PPIs can contribute to hypomagnesemia and vitamin B12
deﬁciency [8].
There is no doubt that incidence, severity and healthcare
burden of C. difﬁcile infection have been increasing in hospi-
tals, nursing homes and the outpatient setting. Although no
randomized controlled studies have been reported, recent
meta-analyses of case-control and cohort studies reached the
same conclusion: PPI use increases the probability of C. difﬁ-
cile infection almost twofold. [9–11] In addition, there may
be an increased risk of recurrent infection if PPIs are adminis-
tered. [10] Not surprisingly, the risk of C. difﬁcile infection is
even higher when PPIs and antibiotics are used concomitantly.
[10] A recent study suggests that an increased risk of C. difﬁcile
infection may be apparent when PPI use exceeds 2 days in
patients without a prior hospitalization and 1 day in patients
with a prior admission. [12]
I believe it is time to re-examine the use of stress ulcer
prophylaxis and the use of PPIs in particular in critically ill
patients. PPIs should only be considered for ICU patients with
a high risk of stress ulcer bleeding. Once the risk of bleeding has
decreased, PPI use should be discontinued. Every effort should
be made to discontinue PPI use in the setting of C. difﬁcile
infection. Unfortunately, PPI use started in the ICU is often
continued as the patient transitions to the general ﬂoor and dis-
charge. PPI use in ICU patients should be reassessed for appro-
priate continuation before transfer to another level of care.
Perhaps PPIs should be added to the daily checklist of items
to discontinue or avoid in ICU patients similar to interventions
such as urinary catheters, central lines, and sedation.
The bottom line is that less use of PPIs in critically ill
patients may be beneﬁcial.References
[1] Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for
gastrointestinal bleeding in critically ill patients. Canadian Critical
Care Trials Group. N Engl J Med 1994;330:377–81.
[2] Ellison RT, Perez-Perez G, Welsh CH, Blaser MJ, Riester KA,
Cross AS, et al. Risk factors for upper gastrointestinal bleeding in
2 Editorialintensive care unit patients: role of Helicobacter pylori. Federal
Hyperimmune Immunoglobulin Therapy Study Group. Crit Care
Med 1996;24:1974–81.
[3] Robertson MS, Wilson SJ, Cade SF. Acute stress ulceration
prophylaxis: point prevalence surveys in intensive care units in
Victoria, 1997 and 2005. Crit Care Resuscitation 2008;10(1):18.
[4] Quenot J-P, Mentec H, Feihl F, Annane D, Melot C, Vignon P,
et al. Bedside adherence to clinical practice guidelines in the
intensive care unit: the TECLA study. Intensive Care Med
2008;34:1393–400.
[5] Daley RD, Rebuck JA, Welage LS, Rogers FB. Prevention of
stress ulceration: current trends in critical care. Crit Care Med
2004;32(10):2008–13.
[6] de Jager CPC, Wever PC, Gemen EFA, et al. Proton pump
inhibitor therapy predisposes to community-acquired Streptococ-
cus pneumoniae pneumonia. Aliment Pharmacol Ther
2012;36:941–9.
[7] Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-
suppressive medication use and the risk for hospital-acquired
pneumonia. JAMA 2009;301(20):2120–8.
[8] Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump
inhibitor and histamine 2 receptor antagonist use and vitamin B12
deﬁciency. JAMA 2013;310(22):2435–42.[9] Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium
difﬁcile-associated diarrhea and proton pump inhibitor therapy: a
meta-analysis. Am J Gastroenterol 2012;107:1001–10.
[10] Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke
YK. Risk of Clostridium difﬁcile infection with acid suppressing
drugs and antibiotics: meta-analysis. Am J Gastroenterol
2012;107:1011–9.
[11] Deshpande A, Pant C, Pasupuleti V, et al. Association between
proton pump inhibitor therapy and Clostridium difﬁcile infection
in a meta-analysis. Clin Gastroenterol Hepatol 2012;10:225–33.
[12] Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR.
Proton pump inhibitors and the risk for hospital-acquired
Clostridium difﬁcile infection. Mayo Clin Proc 2013;88(10):
1085–90.
Janice L. Zimmerman
Head, Division of Critical Care, Department of Medicine,
Houston Methodist Hospital, Houston, TX, United States
Professor of Clinical Medicine, Weill Cornell Medical College,
New York, United States
E-mail address: janicez@houstonmethodist.org
Available online 11 February 2014
